Sentences with phrase «promising vaccine candidates»

TBVAC2020 uses standardised, head - to - head models for the screening of promising vaccine candidates in independent laboratories.

These proteins can be comparatively tested to identify the most promising vaccine candidates, and to understand how the parasite interacts with the human host and cause disease.

Two of the proteins, NGO1985 and NGO2121, showed extensive sensitivity to antimicrobial compounds and thus emerged as the most promising vaccine candidates.

«It's very, very disappointing,» says Heinz Feldmann of NIAID's Rocky Mountain Laboratories in Hamilton, Montana, who has helped develop a promising vaccine candidate.

In order to move forward they made pioneering technological breakthroughs as well, all of which have resulted in the most promising vaccine candidate against malaria to date.

Not exact matches

«World's most advanced dengue vaccine candidate shows promise in phase 3 trial.»

«It's a novel strategy, and it works beautifully,» said senior investigator Harvey M. Friedman, MD, a professor of Infectious Diseases at Penn. «I know of no other HSV2 vaccine candidate with published results that are as promising as this study.»

Many Ebola researchers say they, too, would eagerly try the antibodies — or one of the promising candidate drugs, or an experimental Ebola vaccine.

«We observed rapid and durable protective immunity without adverse events, and so we think this candidate vaccine represents a promising strategy for the global fight against Zika virus,» said senior author Drew Weissman, MD, PhD, a professor of Infectious Disease at Penn. «We hope to start clinical trials in 12 to 18 months.»

«New Zika vaccine candidate protects mice and monkeys with a single dose: Results from study highlight the promise of mRNA - based vaccines and therapies.»

Johns Hopkins Bloomberg School of Public Health researchers say a new candidate vaccine against respiratory syncytial virus (RSV) made with a weakened version of the virus shows great promise at fighting the disease, the leading cause of hospitalization for children under the age of one in the U.S.

Candidate Zika vaccines, which have shown early promise, should be in clinical trials next year.

The Walter Reed Army Institute of Research (WRAIR) and collaborators at the Beth Israel Deaconess Medical Center and Harvard Medical School have completed a promising preclinical study of two Zika vaccine candidates that suggests that an effective human vaccine will be achievable.

Scientists have many promising malaria vaccine candidates in the works, and for the first time one has reached advanced human trials.

Nanotheraputics for Antibiotic Resistent Emerging Bacterial pathogens (NAREB) European Research Infrastructures for Poverty Related Diseases (EURIPED) Biomarkers for enhanced vaccines immunosafety (BioVacSafe) European network of vaccine research and development TRANSVAC Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development (TBVAC2020)

Results from the sporozoite stage vaccine look promising, the blood - stage candidate showed to be safe but will require further development, the transmission blocking candidate showed to be safe and immunogenic and the pre-erythrocytic candidate showed efficacy in UK adults.

In 2015 - 2017, TBVI will continue to support consortium partners to innovate and diversify the vaccine and biomarker pipelines and to move promising candidates through preclinical and early clinical development.

WCBS 880 AM — A «Promising Lead» in Fight Against Pancreatic Cancer - April 4, 2012 Early results from a clinical trial at CINJ show stable disease in pancreatic cancer for certain candidates following vaccine treatment.

«This study allowed us to evaluate the protective efficacy of several prime - boost vaccine combinations, and these data will help guide the advancement of the most promising candidates into clinical trials,» noted lead author Dr. Dan Barouch of Beth Israel Deaconess Medical Center at Harvard Medical School and the Ragon Institute of MGH, MIT, and Harvard.

Among other things, it features articles on new developments in HIV cure research, recent studies that show promise but also possible pitfalls of using adenovirus vectors in HIV vaccine candidates, and the funding crisis at the Global Fund to Fight AIDS, Tuberculosis and Malaria.

Results from an initial study combining a microbicide candidate and experimental vaccine are promising enough to at least keep Imperial College virologist Robin Shattock coming back for more in pursuing what could be a novel move in preventing HIV infection.

A good knowledge of correlates of protection could predict the efficacy of novel vaccines at early stages of development and help identify the most promising candidates for vaccine trials.

We partner with government, academic, and industry experts to explore multiple vaccine concepts simultaneously and advance only the most promising candidates.